**Name of Journal**: *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 47178

**Manuscript Type:** EDITORIAL

**Endoscopic sleeve gastroplasty: From whence we came and where we are going**

de Moura DTH *et al.* Endoscopic sleeve gastroplasty

Diogo Turiani Hourneaux de Moura; Eduardo Guimarães Hourneaux de Moura; Christopher C Thompson

**Diogo Turiani Hourneaux de Moura, Christopher C Thompson,** Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, United States

**Diogo Turiani Hourneaux de Moura, Eduardo Guimarães Hourneaux de Moura,** Department of Endoscopy of Clinics Hospital of São Paulo University, São Paulo 05403-00, Brazil

**ORCID number:** Diogo Turiani Hourneaux de Moura (0000-0002-7446-0355); Eduardo Guimarães Hourneaux de Moura (0000-0002-8023-3722); Christopher C Thompson (0000-0002-6105-5270).

**Author contributions:** de Moura DTH and de Moura EGH conceptualized the study and wrote the manuscript. Thompson CC critical final review of manuscript/English review.

**Conflict-of-interest statement:** de Moura EGH consultant for Boston Scientific and Olympus, de Moura EGH is a consultant to Boston Scientific.Thompson CC reports fee as a consultant for Boston Scientific and Medtronic; fees as consultant and institutional grants from USGE Medical, Olympus, and Apollo Endosurgery.All other authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Diogo Turiani Hourneaux de Moura, MD, MSc, PhD, Academic Fellow, Postdoctoral Fellow, Research Fellow, Surgeon,** Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Harvard Medical School, 45 Francis St, Boston, MA 02115, United States. dthmoura@hotmail.com

**Telephone**:

**Received:** March 11, 2019

**Peer-review started:** March 12, 2019

**First decision:** April 13, 2019

**Revised:** April 16, 2019

**Accepted:** April 18, 2019

**Article in press:** April 18, 2019

**Published online:**May 16, 2019

**Abstract**

The most effective and durable treatment for obesity is bariatric surgery. However, less than 2% of eligible patients who fulfill the criteria for bariatric surgery undergo the procedure. As a result, there is a drive to develop less invasive therapies to combat obesity. Endoscopic bariatric therapies (EBT) for weight loss are important since they are more effective than pharmacological treatments and lifestyle changes and present lower adverse event rates compared to bariatric surgery. Endoscopic sleeve gastroplasty (ESG) is a minimally invasive EBT that involves remodeling of the greater curvature. ESG demonstrated favorable outcomes in several centers, with up to 20.9% total body weight loss and 60.4% excess weight loss (EWL) on 2-year follow-up, with a low rate of severe adverse events (SAE). As such, it could be considered safe and effective in light of ASGE/ASMBS thresholds of > 25% EWL and ≤ 5% SAE, although there are no comparative trials to support this. Additionally, ESG showed improvement in diabetes mellitus type 2, hypertension, and other obesity-related comorbidities. As this procedure continues to develop there are several areas that can be addressed to improve outcomes, including device improvements, technique standardization, patient selection, personalized medicine, combination therapies, and training standardization. In this editorial we discuss the origins of the ESG, current data, and future developments.

**Key words:** Endoscopy; Surgery; Bariatric; Obesity; Overweight; Comorbidities; Gastroplasty; Sleeve; Endoscopic sleeve gastroplasty; Editorial

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Given the worsening obesity epidemic, there is increased demand for less invasive therapies. Considering the minimally invasive nature of Endoscopic sleeve gastroplasty (ESG), the reproducibility among centers, the favorable clinical outcomes in several studies, ESG could be regarded as safe and effective in light of ASGE/ASMBS thresholds of > 25% excess weight loss and ≤ 5% severe adverse events, although there are no comparative trials to support this. As this procedure is more widely adopted, high standards of care must be maintained to guarantee satisfactory clinical outcomes. In this editorial we discuss the origins of the ESG, current data, and future developments.

**Citation:** de Moura DTH, de Moura EGH, Thomspon CC. Endoscopic sleeve gastroplasty: From whence we came and where we are going. *World J Gastrointest Endosc* 2019; 11(5): 322-328

**URL:** https://www.wjgnet.com/1948-5190/full/v11/i5/322.htm

**DOI:** https://dx.doi.org/10.4253/wjge.v11.i5.322

Obesity is a disease that is characterized by inflammation of adipose tissue and increased levels of systemic inflammatory cytokines, which are associated with debilitating comorbidities. Obesity has been deemed a pandemic by the World Health Organization, effecting approximately 700 million adults worldwide with an additional 2 billion overweight. It is associated with metabolic conditions, such as type 2 diabetes, cardiovascular diseases, hyperlipidemia, fatty liver, hypertension, osteoporosis, and other diseases. Additionally, obesity is second only to tobacco as a preventable risk factor for a number of cancers[1,2]. The most effective and durable treatment for obesity is bariatric and metabolic surgery[3-5]. However, disadvantages include the irreversible nature of the procedures and the non-negligible morbidity and mortality rates[6-14]. Furthermore, less than 2% of eligible patients who fulfill the criteria for bariatric surgery undergo the procedure. The reasons for this are multifactorial and likely include perceived surgical risk, morbidity, costs, access, and patient preference[15,16].

As a result, there is a drive to develop less invasive and cost-effective therapies to combat this epidemic. It is well established that a total body weight loss (TWL) of at least 10% is most effective in improving obesity-related comorbidities[17,18]. Lifestyle modifications, diet and pharmacotherapies rarely can achieve 10% TWL, and when initially effective, weight regain is common[19]. Endoscopic bariatric therapies (EBT) are important since they are more effective than pharmacological therapy and lifestyle modification and present lower adverse event rates compared with bariatric surgery[20-23].

In 2011, a joint task force convened by the American Society for Gastrointestinal Endoscopy (ASGE) and the American Society for Metabolic and Bariatric surgery (ASMBS) defined thresholds regarding safety and efficacy for EBT[24,25]. Subsequently, a Preservation and Incorporation of Valuable endoscopic Innovations document was created by the ASGE based on this consensus[26]. The results of this process are described below: (1) For primary obesity therapies in patients with obesity class II and III a minimum of 25% excess weight loss (EWL) at 12 mo, with a statistical difference > 15% above the control group is required; (2) For non-primary EBT such as metabolic therapy, bridging to surgery, and early intervention, a minimum of 5% TWL is necessary; and (3) Serious adverse events ≤ 5% is recommended for all EBT.

An EBT that meets these criteria is considered appropriate to incorporate into clinical practice after adequate training[26].

Endoscopic sleeve gastroplasty (ESG) is an incisionless, minimally invasive technique that involves remodeling of the greater curvature, via the placement of full-thickness sutures, in an effort to reduce gastric capacity and delay gastric emptying[27,28].

ESG with full-thickness suturing has demonstrated clinical effectiveness and safety, nevertheless, the technique continues to evolve. This concept was originally inspired by two older procedures, an abandoned endoscopic technique (endoluminal vertical gastroplasty) performed by Fogel *et al*[29] that focused on emulating a vertical banded gastroplasty along the mid-proximal gastric body not involving the greater curvature, and the surgical gastric imbrication procedure. The original greater curvature ESG performed in 2008 using a superficial suction-based suturing device had limited results due to early suture loss[30,31]. Subsequently, ESG was performed using the current full-thickness suturing device in 2012 by Thompson and Hawes[28,32]. ESG has since been the focus of many studies worldwide. These studies have demonstrated technical feasibility, safety, and efficacy for this procedure in terms of weight loss and resolution of metabolic comorbidities[28,30,31,33-39].

Although the exact mechanisms of weight loss following ESG are not clear, the procedure is performed with the intention of reducing gastric volume and altering motility[27,34,37,38]. This is achieved via a reduction in both gastric width and length. Since the first ESG report, different numbers of sutures, orientation of sutures, spacing and frequency of bites, and tightness of cinching have been reported[40]. A variety of suture patterns have been used, including “M”, “Z”, and “U” patterns[41,42], as the procedure has evolved, with the main focus remaining greater curvature remodeling. An important element of all suture patterns is the distal to proximal movement within each running suture that is placed along the greater curvature, contracting the stomach longitudinally to confer the intended gastric shortening while simultaneously narrowing the lumen. Another difference is the use of reinforcement sutures which may be used in an attempt to further reduce volume, minimize tension on running sutures, and potentially improve durability. Nevertheless, no one suture pattern has yet been proven to achieve better efficacy[33,35,38,40-42]. The durability of weight loss may be less related to suture retention than it is to alteration in gastric function, which may persist even after suture loss. The gastric foreshortening partly reduces fundic capacity, however, this is achieved without placing any stitches directly into the fundus. In fact, the fundus is intentionally avoided to allow formation of a small pocket proximal to the sleeve to serve as a reservoir for food which may contribute to the prolonged gastric retention and improved satiety. Furthermore, fundic tissue is particularly thin and prone to leaks, and is in proximity to the spleen. Avoiding direct suture placement into the fundus minimizes the risk of adverse events.

As with many other novel procedures, in the beginning ESG was seen with a mix of enthusiasm and caution by the medical community. ESG was considered by some as a revolutionary technique that would treat obesity with the same efficacy as bariatric surgery. However, others remembered the transient effects of procedures performed with partial-thickness suturing devices that were plagued by early suture loss, and were far more skeptical. The results of the new ESG studies were not superior or similar to bariatric surgery in terms of efficacy, although they realized significant weight loss with fewer adverse events. On long-term follow-up endoscopy the stomach appears to be similar to its original size, however, with some peripheral bridging of tissue, and questions remain regarding the durable impact this may have on gastric function and long-term weight loss.

The largest ESG study, including 1000 patients, was recently published[39]. This study showed satisfactory results of ESG in the management of obesity with a mean %TWL at 6, 12, and 18 mo of 13.7% ± 6.8%, 15.0% ± 7.7%, and 14.8% ± 8.5%, respectively. The mean %EWL at 6, 12, and 18 mo were 64.3% ± 56.2%, 67.5% ± 52.3%, and 64.7% ± 55.4%, respectively. There are two multicenter studies[33,43] evaluating ESG in obese patients. In the study[43] including 112 consecutive patients, the average %TWL and %EWL were 11.9% and 39.9% at 3 mo, and 14.9% and 50.3% at 6 mo follow-up, respectively. By 6 mo post-ESG, 81% and 53.8% of patients had a %TWL greater than 10% and 15 %, respectively. The proportion of patients who achieved greater than 25% EWL was 86.5% at 6 mo. The other multicenter study[33], including 248 patients, reported the longest ESG follow-up to date. At 6 mo and 24 mo, %TWL was 15.2% and 18.6%, respectively, with similar weight loss between centers. The percentage of patients achieving ≥ 10% TWL was 84.2%. Additionally, in both univariable and multivariable regression analysis, weight loss at 6 mo predicted weight maintenance at 24 mo. Achieving less than 10% TWL at 6 mo was an early predictor of poor long-term results and adjunctive therapy to enhance weigh loss in these patients may be recommended. Lopez-Nava *et al*[44], also reported results up to 2 years follow-up. At 24 mo after the procedure baseline mean body mass index (BMI) changed from 38.3 to 30.8 kg/m2; %TWL and %EWL were 19.5% and 60.4%, respectively. In this study, 85.7% of patients achieve greater than 25% EWL.

Most studies report the success of ESG specifically for weight loss. However, some studies also analyzed comorbidities related to obesity[38,39]. Sharaiha *et al*[38] studied 91 patients with BMI higher than 30 kg/m2 who underwent ESG, with a follow-up up to 24 mo. Patients had significant reductions in levels of hemoglobinA1c, systolic blood pressure, waist circumference, alanine aminotransferase, and serum triglycerides. In this study a mean %TWL of 14.4%, 17.6%, and 20.9% were reported at 6 months, 1 year, and 2 year follow-up. Alqahtani *et al*[39] reported 76.5% complete remission in type 2 diabetes by the third month following the procedure, with all remaining patients showing improvement. Additionally, all patients with hypertension and dyslipidemia had complete remission at the time of last follow-up. Despite few studies evaluating obesity-related comorbidities, these results are in keeping with what would be expected with this degree of weight loss.

Procedure durability remains unclear, as the longest follow-up published to date is 2 years[33,44]. It is important to note that redo ESG is an available minimally invasive option. Combination with medical therapy is also effective and should be considered for weight maintenance as needed. Additionally, if ESG fails, bariatric surgery is not contraindicated and has been shown to be effective. A major concern regarding surgical conversion is that the suture T-tags may cause the stapler to misfire resulting in a leak. However, in most suture patterns the gastric cardia is spared, minimizing this risk in conversion to RYGB. Additionally, conversion to sleeve gastrectomy has been successfully performed without adverse events[39].

Overall ESG is well tolerated. In the literature, mild and moderate adverse events such as abdominal pain, nausea and emesis are usually not analyzed in detail because they are expected and managed conservatively with improvement after few days[34,37,41]. A recent study[39] reported 92.4% of nausea or abdominal pain controlled with medication and resolved during the first week. Of 1000 patients, 24 were readmitted with no mortality. Causes for readmission included: severe abdominal pain, postprocedure bleeding, perigastric fluid collection, and post procedure fever. Additionally, another study[45] reported 24.2% moderate abdominal pain and 31.2% nausea and emesis in the first 48 h. Compared to other endoscopic techniques, ESG appears to have favorable outcomes regarding these symptoms. Intragastric balloons and duodenal jejunal bypass sleeves are also associated with approximately 7% and 18% early removals, respectively[26], whereas ESG reversal is extremely rare[39]. In the largest series of ESG, only 0.003% of procedures required reversal due to persistent symptoms[39]. Severe adverse events (SAE) after ESG are rare[27,34-36,43]. A recent review[42], including 9 ESG studies reported a 2.3% SAE rate, including gastric leaks, perigastric fluid collections, pulmonary embolism and pneumoperitoneum with pneumothorax. In the literature there are 7 reports of gastric leaks/perigastric fluid collections and all of these cases were treated without surgical intervention[33,38,39,46]. In general, ESG is associated with a lower rate of SAE, and no mortality, compared to surgical bariatric procedures which has up to a 20% SAE rate with 0.04% mortality rate[9,47,48] Additionally, the SAE rate of less than 5% achieves the threshold set by ASGE/ASMBS position paper[24,25].

ESG studies notably demonstrate some variability in weight loss outcomes, ranging from 15% to 19% TWL at 1 year[28,39]. The reasons for this are unclear and likely multifactorial. Baseline patient characteristics, number of sutures, suture pattern, use of reinforcement sutures, post-procedure diet, concomitant weight loss medication use, intensity of life-style modification, and follow-up plan of care all may be important factors influencing these results. Number of sutures and pattern are particularly important from a financial standpoint for many centers. Using fewer sutures is less costly and reduces procedure time, which ultimately may allow broader adoption. Although there is no rigorous evidence regarding number of sutures or ideal pattern, we believe that reinforcement sutures are associated with better efficacy and should be incorporated into suture patterns when possible. Post-procedure plan of care also differs among centers with unique diet recommendations, follow-up schedules, and pharmacotherapy use, which no doubt impact clinical outcomes and likely contribute to this variability as well.

In addition to ideal technique, experience level and patient characteristics required for optimal outcomes are also not well understood. Regarding recommended experience level, a multicenter study[31] showed that 34 cases were statistically significant to achieve a satisfactory %TWL, however, no formal learning curve assessment was performed. Similarly, there are little data to guide patient selection. A univariable analysis showed that younger age was significantly associated with weight loss at 1-year follow-up. Additionally, as one proposed mechanism is prolonged gastric retention, patients with underlying gastroparesis may be poorer candidates for this procedure.

As this field continues to develop there are several areas that can be addressed to improve outcomes. We are already seeing procedure and device improvements to simplify technical aspects and enhance durability. Technique standardization is still needed and will likely occur when better data are available. Patient selection is always an important consideration for optimizing patient outcomes. Moving towards personalized medicine, several factors are being investigated including baseline demographics, gastric motility, autonomic function, bile acid metabolism, gut hormones, genetics, and microbiome. Combination therapies also hold the promise of improved efficacy. Endoscopic device combinations, applied simultaneously or sequentially, that employ different mechanisms of action and combination with pharmacotherapies are now actively being studied. It is also time for randomized controlled trials to better address many of these questions and provide level 1A evidence to confirm satisfactory outcomes. This will also help establish best medical practices and contribute towards broader reimbursement. Finally, as use of this procedure grows, standardized training and credentialing processes will be required to ensure patient safety and maintain good clinical outcomes.

In summary, given the worsening obesity epidemic, there is increased demand for less invasive bariatric therapies. Considering the minimally invasive outpatient nature of ESG, the reproducibility among centers with different experience levels, and the favorable clinical outcomes in several studies, ESG could be regarded as safe and effective in light of ASGE/ASMBS thresholds of > 25% EWL and ≤ 5% severe adverse events, however, there are no comparative trials to date. As this procedure is more widely adopted, high standards of care must be maintained to guarantee satisfactory clinical outcomes.

**REFERENCES**

1 **World Health Organization.** Obesity and overweight. 2018 Available from: http://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

2 **Rønningen R**, Wammer ACP, Grabner NH, Valderhaug TG. Associations between Lifetime Adversity and Obesity Treatment in Patients with Morbid Obesity. *Obes Facts* 2019; **12**: 1-13 [PMID: 30654360 DOI: 10.1159/000494333]

3 **Ruiz-Cota P**, Bacardí-Gascón M, Jiménez-Cruz A. Long-term outcomes of metabolic and bariatric surgery in adolescents with severe obesity with a follow-up of at least 5 years: A systematic review. *Surg Obes Relat Dis* 2019; **15**: 133-144 [PMID: 30514669 DOI: 10.1016/j.soard.2018.10.016]

4 **Khosravi-Largani M,** Nojomi M, Aghili R, Otaghvar HA, Tanha K, Seyedi SHS, Mottaghi A. Evaluation of all Types of Metabolic Bariatric Surgery and its Consequences: a Systematic Review and Meta-Analysis. *Obes Surg* 2019; **29**: 651-690 [DOI: 10.1007/s11695-018-3550-z]

5 **Barrichello S**, Minata MK, García Ruiz de Gordejuela A, Bernardo WM, de Souza TF, Galvão Neto M, Hourneaux de Moura DT, Santo MA, Hourneaux de Moura EG. Laparoscopic Greater Curvature Plication and Laparoscopic Sleeve Gastrectomy Treatments for Obesity: Systematic Review and Meta-Analysis of Short- and Mid-Term Results. *Obes Surg* 2018; **28**: 3199-3212 [PMID: 29951784 DOI: 10.1007/s11695-018-3330-9]

6 **Longitudinal Assessment of Bariatric Surgery (LABS) Consortium.**, Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E, Pomp A, Staten MA, Yanovski SZ, Thirlby R, Wolfe B. Perioperative safety in the longitudinal assessment of bariatric surgery. *N Engl J Med* 2009; **361**: 445-454 [PMID: 19641201 DOI: 10.1056/NEJMoa0901836]

7 **Obeid NR**, Malick W, Concors SJ, Fielding GA, Kurian MS, Ren-Fielding CJ. Long-term outcomes after Roux-en-Y gastric bypass: 10- to 13-year data. *Surg Obes Relat Dis* 2016; **12**: 11-20 [PMID: 26410537 DOI: 10.1016/j.soard.2015.04.011]

8 **de Moura DTH**, Ribeiro IB, Funari MP, Baptista A, Thompson CC, de Moura EGH. Novel use of a cardiac septal occluder to treat a chronic recalcitrant bariatric fistula after Roux-en-Y gastric bypass. *Endoscopy* 2019 [PMID: 30791049 DOI: 10.1055/a-0842-6287]

9 **Baptista A,** De Moura DTH, Jirapinyo P, De Moura EGH, Gelrud A, Kahaleh M, Salinas A, Sabagh LC, Jaramillo AO, Rincones VZ, Doval R, Bandel JW, Thompson CC. Efficacy of the cardiac septal occluder in the treatment of post-bariatric surgery leaks and fistulas. *Gastrointest Endosc* 2018; **89**: 671-679 [DOI: 10.1016/j.gie.2018.11.034]

10 **de Moura DTH**, de Moura EGH, Neto MG, Thompson CC. To the Editor. *Surg Obes Relat Dis* 2019; **15**: 155-157 [PMID: 30477752 DOI: 10.1016/j.soard.2018.10.006]

11 **Haito-Chavez Y**, Kumbhari V, Ngamruengphong S, De Moura DT, El Zein M, Vieira M, Aguila G, Khashab MA. Septotomy: an adjunct endoscopic treatment for post-sleeve gastrectomy fistulas. *Gastrointest Endosc* 2016; **83**: 456-457 [PMID: 26358326 DOI: 10.1016/j.gie.2015.08.065]

12 **de Moura DTH**, Sachdev AH, Thompson CC. Endoscopic Full-Thickness Defects and Closure Techniques. *Curr Treat Options Gastroenterol* 2018; **16**: 386-405 [PMID: 30382572 DOI: 10.1007/s11938-018-0199-6]

13 **de Moura DTH**, Jirapinyo P, Aihara H, Thompson CC. Endoscopic tunneled stricturotomy in the treatment of stenosis after sleeve gastrectomy. *VideoGIE* 2018; **4**: 68-71 [PMID: 30766946 DOI: 10.1016/j.vgie.2018.09.013]

14 **de Moura EG**, Galvão-Neto MP, Ramos AC, de Moura ET, Galvão TD, de Moura DT, Ferreira FC. Extreme bariatric endoscopy: stenting to reconnect the pouch to the gastrojejunostomy after a Roux-en-Y gastric bypass. *Surg Endosc* 2012; **26**: 1481-1484 [PMID: 22179450 DOI: 10.1007/s00464-011-2060-z]

15 **Buchwald H**, Oien DM. Metabolic/bariatric surgery worldwide 2011. *Obes Surg* 2013; **23**: 427-436 [PMID: 23338049 DOI: 10.1007/s11695-012-0864-0]

16 **Madruga-Neto AC**, Bernardo WM, de Moura DTH, Brunaldi VO, Martins RK, Josino IR, de Moura ETH, de Souza TF, Santo MA, de Moura EGH. The Effectiveness of Endoscopic Gastroplasty for Obesity Treatment According to FDA Thresholds: Systematic Review and Meta-Analysis Based on Randomized Controlled Trials. *Obes Surg* 2018; **28**: 2932-2940 [PMID: 29909512 DOI: 10.1007/s11695-018-3335-4]

17 **Vilar-Gomez E**, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology* 2015; **149**: 367-78.e5; quiz e14-5 [PMID: 25865049 DOI: 10.1053/j.gastro.2015.04.005]

18 **Daniel S**, Soleymani T, Garvey WT. A complications-based clinical staging of obesity to guide treatment modality and intensity. *Curr Opin Endocrinol Diabetes Obes* 2013; **20**: 377-388 [PMID: 23974764 DOI: 10.1097/01.med.0000433067.01671.f5]

19 **Wing RR**, Espeland MA, Clark JM, Hazuda HP, Knowler WC, Pownall HJ, Unick J, Wadden T, Wagenknecht L; Action for Health in Diabetes (Look AHEAD) Study Group. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. *Diabetes Care* 2016; **39**: 1345-1355 [PMID: 27271190 DOI: 10.2337/dc16-0509]

20 **Moura D**, Oliveira J, De Moura EG, Bernardo W, Galvão Neto M, Campos J, Popov VB, Thompson C. Effectiveness of intragastric balloon for obesity: A systematic review and meta-analysis based on randomized control trials. *Surg Obes Relat Dis* 2016; **12**: 420-429 [PMID: 26968503 DOI: 10.1016/j.soard.2015.10.077]

21 **Bustamante F**, Brunaldi VO, Bernardo WM, de Moura DTH, de Moura ETH, Galvão M, Santo MA, de Moura EGH. Obesity Treatment with Botulinum Toxin-A Is Not Effective: a Systematic Review and Meta-Analysis. *Obes Surg* 2017; **27**: 2716-2723 [PMID: 28812212 DOI: 10.1007/s11695-017-2857-5]

22 **Hourneaux De Moura DT**, Thompson CC. Endoscopic management of weight regain following Roux-en-Y gastric bypass. *Expert Rev Endocrinol Metab* 2019; **14**: 97-110 [PMID: 30691326 DOI: 10.1080/17446651.2019.1571907]

23 **Brunaldi VO**, Jirapinyo P, de Moura DTH, Okazaki O, Bernardo WM, Galvão Neto M, Campos JM, Santo MA, de Moura EGH. Endoscopic Treatment of Weight Regain Following Roux-en-Y Gastric Bypass: a Systematic Review and Meta-analysis. *Obes Surg* 2018; **28**: 266-276 [PMID: 29082456 DOI: 10.1007/s11695-017-2986-x]

24 **ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy.**. A pathway to endoscopic bariatric therapies. *Surg Obes Relat Dis* 2011; **7**: 672-682 [PMID: 22082971 DOI: 10.1016/j.soard.2011.09.008]

25 **ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy.**, Ginsberg GG, Chand B, Cote GA, Dallal RM, Edmundowicz SA, Nguyen NT, Pryor A, Thompson CC. A pathway to endoscopic bariatric therapies. *Gastrointest Endosc* 2011; **74**: 943-953 [PMID: 22032311 DOI: 10.1016/j.gie.2011.08.053]

26 **ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee.**, Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, Sullivan S, Thompson CC, Banerjee S. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. *Gastrointest Endosc* 2015; **82**: 425-38.e5 [PMID: 26232362 DOI: 10.1016/j.gie.2015.03.1964]

27 **Lopez-Nava G**, Galvão MP, Bautista-Castaño I, Jimenez-Baños A, Fernandez-Corbelle JP. Endoscopic Sleeve Gastroplasty: How I Do It? *Obes Surg* 2015; **25**: 1534-1538 [PMID: 26003549 DOI: 10.1007/s11695-015-1714-7]

28 **Kumar N,** Lopez-Nava G, Sahdala HNP, Manoel GN, Sharaiha RZ, Wilson EB, Shaikh S, Gomez E, Ryan MB, Zundel N, Thompson CC. 934 Endoscopic Sleeve Gastroplasty: Multicenter Weight Loss Results. *Gastroenterology* 2015; **148**: S-179 [DOI: 10.1016/S0016-5085(15)30597-7]

29 **Fogel R**, De Fogel J, Bonilla Y, De La Fuente R. Clinical experience of transoral suturing for an endoluminal vertical gastroplasty: 1-year follow-up in 64 patients. *Gastrointest Endosc* 2008; **68**: 51-58 [PMID: 18355825 DOI: 10.1016/j.gie.2007.10.061]

30 **Brethauer SA**, Chand B, Schauer PR, Thompson CC. Transoral gastric volume reduction for weight management: technique and feasibility in 18 patients. *Surg Obes Relat Dis* 2010; **6**: 689-694 [PMID: 20947451 DOI: 10.1016/j.soard.2010.07.012]

31 **Brethauer SA**, Chand B, Schauer PR, Thompson CC. Transoral gastric volume reduction as intervention for weight management: 12-month follow-up of TRIM trial. *Surg Obes Relat Dis* 2012; **8**: 296-303 [PMID: 22178565 DOI: 10.1016/j.soard.2011.10.016]

32 **Neto MG,** Zundel N, Campos J, Alvarado A, Silva L, Orilaac J, Shaikh S, Gomez E, Wilson E, Thompson CC. ET010 Endoluminal greater curvature plication - A case series. *SAGES* 2013 Available from: https://www.sages.org/meetings/annual-meeting/abstracts-archive/endoluminal-greater-curvature-plication-a-case-series/

33 **Lopez-Nava G**, Sharaiha RZ, Vargas EJ, Bazerbachi F, Manoel GN, Bautista-Castaño I, Acosta A, Topazian MD, Mundi MS, Kumta N, Kahaleh M, Herr AM, Shukla A, Aronne L, Gostout CJ, Abu Dayyeh BK. Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up. *Obes Surg* 2017; **27**: 2649-2655 [PMID: 28451929 DOI: 10.1007/s11695-017-2693-7]

34 **Sharaiha RZ**, Kedia P, Kumta N, DeFilippis EM, Gaidhane M, Shukla A, Aronne LJ, Kahaleh M. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. *Endoscopy* 2015; **47**: 164-166 [PMID: 25380510 DOI: 10.1055/s-0034-1390773]

35 **Lopez-Nava G**, Galvão MP, da Bautista-Castaño I, Jimenez A, De Grado T, Fernandez-Corbelle JP. Endoscopic sleeve gastroplasty for the treatment of obesity. *Endoscopy* 2015; **47**: 449-452 [PMID: 25380508 DOI: 10.1055/s-0034-1390766]

36 **Galvão-Neto MD**, Grecco E, Souza TF, Quadros LG, Silva LB, Campos JM. ENDOSCOPIC SLEEVE GASTROPLASTY - MINIMALLY INVASIVE THERAPY FOR PRIMARY OBESITY TREATMENT. *Arq Bras Cir Dig* 2016; **29Suppl 1**: 95-97 [PMID: 27683786 DOI: 10.1590/0102-6720201600S10023]

37 **Abu Dayyeh BK**, Acosta A, Camilleri M, Mundi MS, Rajan E, Topazian MD, Gostout CJ. Endoscopic Sleeve Gastroplasty Alters Gastric Physiology and Induces Loss of Body Weight in Obese Individuals. *Clin Gastroenterol Hepatol* 2017; **15**: 37-43.e1 [PMID: 26748219 DOI: 10.1016/j.cgh.2015.12.030]

38 **Sharaiha RZ**, Kumta NA, Saumoy M, Desai AP, Sarkisian AM, Benevenuto A, Tyberg A, Kumar R, Igel L, Verna EC, Schwartz R, Frissora C, Shukla A, Aronne LJ, Kahaleh M. Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients. *Clin Gastroenterol Hepatol* 2017; **15**: 504-510 [PMID: 28017845 DOI: 10.1016/j.cgh.2016.12.012]

39 **Alqahtani A,** Al-Darwish A, Mahmoud AE, Alqahtani YA, Elahmedi M. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. *Gastrointest Endosc* 2018 [DOI: 10.1016/j.gie.2018.12.012]

40 **Kumar N**, Abu Dayyeh BK, Lopez-Nava Breviere G, Galvao Neto MP, Sahdala NP, Shaikh SN, Hawes RH, Gostout CJ, Goenka MK, Orillac JR, Alvarado A, Jirapinyo P, Zundel N, Thompson CC. Endoscopic sutured gastroplasty: procedure evolution from first-in-man cases through current technique. *Surg Endosc* 2018; **32**: 2159-2164 [PMID: 29075966 DOI: 10.1007/s00464-017-5869-2]

41 **Graus Morales J,** Crespo Pérez L, Marques A, Marín Arribas B, Bravo Arribas R, Ramo E, Escalada C, Arribas C, Himpens J. Modified endoscopic gastroplasty for the treatment of obesity. *Surg Endosc* 2018; **32**: 3936-3942 [DOI: 10.1007/s00464-018-6133-0]

42 **Jain D**, Bhandari BS, Arora A, Singhal S. Endoscopic Sleeve Gastroplasty - A New Tool to Manage Obesity. *Clin Endosc* 2017; **50**: 552-561 [PMID: 28607328 DOI: 10.5946/ce.2017.032]

43 **Sartoretto A**, Sui Z, Hill C, Dunlap M, Rivera AR, Khashab MA, Kalloo AN, Fayad L, Cheskin LJ, Marinos G, Wilson E, Kumbhari V. Endoscopic Sleeve Gastroplasty (ESG) Is a Reproducible and Effective Endoscopic Bariatric Therapy Suitable for Widespread Clinical Adoption: a Large, International Multicenter Study. *Obes Surg* 2018; **28**: 1812-1821 [PMID: 29450845 DOI: 10.1007/s11695-018-3135-x]

44 **Lopez-nava G,** Galvão MP, Bautista-castaño I, Fernandez-corbelle JP, Trell M, Lopez N. Endoscopic sleeve gastroplasty for obesity treatment: two years of experience. *ABCD* *Arq Bras Cir Dig* 2017; **30**: 18–20 [DOI: 10.1590/0102-6720201700010006]

45 **Saumoy M**, Schneider Y, Zhou XK, Shukla A, Kahaleh M, Aronne L, Sharaiha RZ. A single-operator learning curve analysis for the endoscopic sleeve gastroplasty. *Gastrointest Endosc* 2018; **87**: 442-447 [PMID: 28843586 DOI: 10.1016/j.gie.2017.08.014]

46 **Barola S**, Agnihotri A, Khashab MA, Kumbhari V. Perigastric fluid collection after endoscopic sleeve gastroplasty. *Endoscopy* 2016; **48**: E340-E341 [PMID: 27741534 DOI: 10.1055/s-0042-117844]

47 **Trastulli S**, Desiderio J, Guarino S, Cirocchi R, Scalercio V, Noya G, Parisi A. Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. *Surg Obes Relat Dis* 2013; **9**: 816-829 [PMID: 23993246 DOI: 10.1016/j.soard.2013.05.007]

48 **Sakran N**, Sherf-Dagan S, Blumenfeld O, Romano-Zelekha O, Raziel A, Keren D, Raz I, Hershko D, Gralnek IM, Shohat T, Goitein D. Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study. *Obes Surg* 2018; **28**: 2661-2669 [PMID: 29627947 DOI: 10.1007/s11695-018-3212-1]

**P-Reviewer:** Isik A, Lee SC **S-Editor:** Dou Y **L-Editor:** A **E-Editor:** Xing YX

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0